Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Poop pills for painful skin? fecal transplant trial targets hidradenitis

NCT ID NCT07668713

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether fecal microbiota transplantation (FMT) can improve moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Researchers will give 24 adults a single FMT and track changes in their skin lesions over 12 weeks. The goal is to see if altering gut bacteria can reduce inflammation and flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fecal microbiota transplantation (FMT)
What this could lead to
If it works, this could point toward a new treatment option for hidradenitis suppurativa by restoring healthy gut bacteria.
What could go wrong
This is a very early phase 1 pilot with only 24 participants, so results may not apply broadly. FMT carries risks of infection or digestive upset, and the effect on HS is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Patient with Hurley HS II (moderate severity) or III (very severe) * Axillomammary (LC1) or gluteal (LC3) phenotype with at least 4 inflammatory lesions: inflammatory nodule, abscess or active fistula * Having presented at least one relapse to a well-conducted medical treatment as proposed by the 2019 French Dermatology Society evidence center recommendations (broad-spectrum antibiotic therapy for 15 to 21 days followed by prophylactic treatment with doxycycline or cotrimoxazole). A relapse is defined as the occurrence of a new attack within 3 months of the introduction of treatment. Exclusion Criteria: * Allergy or contraindication to amoxicillin-clavulanic acid * Patient having received biomedication in the 3 months prior to inclusion * Patient suffering from another inflammatory disease (IBD, inflammatory rheumatism, auto-inflammatory disease) * Concomitant Clostridioides Difficile infection * Immunocompromised patients * HIV infection and active HBV/HCV hepatitis * No health insurance * Pregnant or breast-feeding women * Patients already included in a biomedical research study other than an observational study (e.g. registry, cohort) * Patients under guardianship/curatorship/legal protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fecal microbiota transplantation (FMT) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fecal microbiota transplantation (FMT) Hidradenitis suppurativa (HS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Rodez

    Rodez, France

  • CHU Bordeaux, Hôpital Saint-André

    Bordeaux, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, France

  • CHU Clermont Ferrand, PIC/CIC

    Clermont-Ferrand, France

  • CHU Lyon

    Lyon, France

  • CHU Marseille, La Timone

    Marseille, France

  • CHU Montpellier

    Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.